Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the eects of curcumin on cognitive decline.

Gagliardi, S., Morasso, C., Stivaktakis, P., Pandini, C., Tinelli, V., Tsatsakis, A., et al. (2020). Curcumin Formulations and Trials: What’s New in Neurological Diseases. MOLECULES, 25(22) [10.3390/molecules25225389].

Curcumin Formulations and Trials: What’s New in Neurological Diseases

Prosperi, Davide;
2020

Abstract

Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the eects of curcumin on cognitive decline.
Articolo in rivista - Review Essay
curcumin; neurological diseases; nanoformulation; clinical trials
English
18-nov-2020
2020
25
22
5389
none
Gagliardi, S., Morasso, C., Stivaktakis, P., Pandini, C., Tinelli, V., Tsatsakis, A., et al. (2020). Curcumin Formulations and Trials: What’s New in Neurological Diseases. MOLECULES, 25(22) [10.3390/molecules25225389].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/294768
Citazioni
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 15
Social impact